Research programme: macrophage metalloelastase inhibitors - NovartisAlternative Names: Macrophage metalloelastase inhibitors research programme - Novartis; MME inhibitors research programme - Novartis; Research programme: MME inhibitors - Novartis
Latest Information Update: 14 Aug 2001
At a glance
- Originator Novartis
- Mechanism of Action Matrix metalloproteinase 12 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Emphysema
Most Recent Events
- 14 Aug 2001 No-Development-Reported for Emphysema in USA (Unknown route)
- 13 Aug 1998 New profile
- 13 Aug 1998 Preclinical development for Emphysema in USA (Unknown route)